The overexpression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is tied to poor prognosis in several cancer types, including osteosarcoma and Ewing sarcoma, and is therefore a potential therapeutic target in these cancers. In this regard, Avammune Therapeutics Inc. is developing an ENPP1 inhibitor – AVA-NP-695.
Receptor-interacting protein kinase 1 (RIPK1) helps promote the survival of cancer cells, and degrading it can sensitize tumors to immunotherapy against PD-1. Degrading the entire protein seems to be essential: merely blocking its kinase activity does not sensitize tumors.
Avencell Therapeutics Inc. has received clinical trial clearances from the FDA and EMA to conduct a phase I/II trial (Quadvance) of AVC-203 for the treatment of relapsed or refractory B-cell malignancies.
A recently published study, conducted by researchers from Jinan University and collaborating institutions, aimed to investigate the mechanisms of endometriosis-driven carcinogenesis.
Crescent Biopharma Inc. has announced a new partnership with Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. and reported progress across its pipeline, with three distinct programs set to enter the clinic next year.
Qingdao Putaike Biomedical Technology Co. Ltd. has divulged hydrophobic tag-based degraders comprising heat shock protein 90 (HSP90) ligands covalently linked to an androgen receptor (AR)-targeting moiety through a linker acting as AR degradation inducers reported to be useful for the treatment of acne, androgenic alopecia, hirsutism, metabolic disorders, breast cancer and prostate cancer.
Zhejiang Yangli Pharmaceutical Technology Co. Ltd. has synthesized thiazole-substituted pyrimidine amine compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.
Université de Montréal has disclosed GTPase KRAS G12D mutant inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and immunological disorders.
Abilita Therapeutics Inc. has developed a novel approach targeting CCR8 – ABT-863 – that works as a potent inverse agonist to block CCL1-dependent and basal receptor signaling.
RSS
